Abstract
Children, adolescents, and young people living with HIV (CALWHIV), including those in resource-limited settings, may be at increased risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, poorer coronavirus disease 2019 (COVID-19) outcomes, and multisystem inflammatory syndrome (MIS). We conducted a repeat SARS-CoV-2 seroprevalence survey among CALWHIV in Europe (n = 493) and South Africa (SA, n = 307), and HIV-negative adolescents in SA (n = 100), in 2020-2022. Blood samples were tested for SARS-CoV-2 antibody, questionnaires collected data on SARS-CoV-2 risk factors and vaccination status, and clinical data were extracted from health records. SARS-CoV-2 seroprevalence (95% CI) was 55% (50%-59%) in CALWHIV in Europe, 67% (61%-72%) in CALWHIV in SA, and 85% (77%-92%) among HIV-negative participants in SA. Among those unvaccinated at time of sampling (n = 769, 85%), seroprevalence was 40% (35%-45%), 64% (58%-70%), and 81% (71%-89%), respectively. Few participants (11% overall) had a known history of SARS-CoV-2-positive PCR or self-reported COVID-19. Three CALWHIV were hospitalized, two with COVID-19 (nonsevere disease) and one young adult with MIS. Although SARS-CoV-2 seroprevalence was high across all settings, even in unvaccinated participants, it was broadly comparable to general population estimates, and most infections were mild/asymptomatic. Results support policy decisions excluding CALWHIV without severe immunosuppression from high-risk groups for COVID-19.